Popular Articles
Burdock Root

New Study Shows Nexium 40 Mg And 20 Mg Reduced Gastric And Duodenal Ulcers By 80 - 85% In Patients Taking Low-Dose Aspirin For CV Protection
Esomeprazole significantly reduced the occurrence of gastric and duodenal ulcers and upper gastrointestinal (GI) symptoms in patients taking low-dose aspirin for risk reduction of adverse cardiovascular (CV) events[i], such as myocardial infarction (MI) and ischaemic stroke, according to new data presented today at the Digestive Diseases Week annual meeting (DDW, 30thMay - 4th June, Chicago).
generic viagra online
Sixteen States, DOJ Join Whistle-Blower Lawsuits Alleging Wyeth Defrauded Medicaid Programs
The U.S. Department of Justice and 16 states have joined two whistle-blower lawsuits filed in federal District Court in Massachusetts alleging that Wyeth defrauded the government by not offering the same discounts on two medications to Medicaid that it offered to hospitals, the Wall Street Journal reports. The lawsuits were initiated following a grand-jury investigation by the U.S. Attorney"s Office in Massachusetts (Johnson, Wall Street Journal, 5/19). The other states included in the lawsuits are California, Delaware, Florida, Illinois, Indiana, Louisiana, New York, Michigan, Nevada, New Hampshire, Tennessee, Texas, Virginia, Wisconsin and the District of Columbia (Barrett, AP/Austin American-Statesman, 5/18).According to the lawsuits, Wyeth from 2000 to 2006 sold hospitals a bundled package called the Protonix Performance Agreement, which included its acid-reflux drugs Protonix Oral and Protonix IV. The suits allege that Wyeth gave hospitals up to a 94% discount for the oral version under the deal, with the understanding that when patients were released from hospitals they would be switched from the intravenous version of the drug to the oral version. According to the complaint, Wyeth hoped to gain an edge in a competitive market for acid-reflux pills by taking advantage of its standing as the only company offering an IV acid-reflux drug. The Journal reports that Wyeth charged hospitals $20 per vial for the IV version of Protonix and $3 for the oral version.Medicaid rules stipulate that the program is entitled to the lowest price on prescription drugs, and drugmakers are required to pay states rebates if they offer discounts to any other entities. The lawsuits state that Wyeth avoided paying hundreds of millions of dollars to state Medicaid programs because it did not offer the programs the same discounts or provide rebates (Wall Street Journal, 5/19).The lawsuits are seeking financial penalties against Wyeth of up to three times the amount lost by Medicaid. Assistant Attorney General Tony West said, "By offering massive discounts to hospitals, but then hiding that information from the Medicaid program, we believe Wyeth caused Medicaid programs throughout the country to pay much more for these drugs than they should have." Wyeth spokesperson Doug Petkus said that Wyeth "believes that its pricing calculations were correct and intends to defend itself vigorously in these actions" (AP/Austin American-Statesman, 5/18).
News of the day
Numbers Of Stroke Caused By Intracerebral Haemorrhage Have Increased By Around A Fifth In The Last Decade
Stokes caused by non-traumatic intracerebral haemorrhage (IH) are caused by a rupture of blood vessels in the brain. This is a major public health problem which accounts for 2 million (10-15%) of a total of 15 million strokes worldwide each year. The causes and the future treatment of this condition are discussed in a Seminar in this week"s edition of The Lancet, written by Dr Adnan I. Qureshi, (Zeenat Qureshi Stroke Research Center, University of Minnesota, USA); Dr A David Mendelow (University of Newcastle, UK); and Dr Daniel F Hanley (Johns Hopkins Medical Institutions, Baltimore, USA).
Medical Devices

Improved Communication Encourages Patients To Seek Colorectal Cancer Screening, Study Finds

Improved communication among patients and primary care physicians increases the chances those due for colorectal cancer screening will follow their doctors" advice and complete the procedure, a University at Buffalo study has found. The research by principal investigator Thomas Feeley, Ph.D., UB associate professor and a specialist in health communication, also found the more convenient the screening process was, the greater the chance patients would follow through and be tested for colon cancer. Feeley holds faculty appointments in communication, family medicine and nursing at UB. The study appears in the June issue of Health Communication. "It became apparent during the study," says Feeley, "that the communication related to cancer screening between health care provider and patient was positively related to an individual going through with the screening recommendation of the physician." Feeley"s research, based on 27 one-hour focus groups with patients, physicians, nurse practitioners and physicians" assistants, found lack of time, patient reluctance and difficulty in scheduling the test itself as reasons people ignored or failed to follow the recommendations made by their primary care physician. Physician recommendation and knowing someone who has or had cancer were the most common factors motivating patients" decisions to complete colorectal cancer screening, the study concludes. James Cooper and Martin C. Mahoney, both of Roswell Park Cancer Institute, and Thomas Foels of Independent Health Association were co-investigators on the study. The study identified a host of reasons why patients whose doctors had recommended they undergo this test avoided doing so. The reasons included fear of the test, embarrassment, fear of the results, the cost of the test and lack of time. The study found several effective measures physicians can take to help their patients overcome the barriers and take the screening test: The more persistent doctors were in discussing colon cancer screening with patients, the more likely the patients would take the test. When the office personnel of primary care doctors scheduled the test for their patients, the "attrition levels" between the time the physician recommended the test and when these patients actually underwent the test decreased, according to patients" testimony. In other words, the more involved the doctor"s office was in the tests, the greater the chances patients would actually go through with the test. The vicarious experience of patients facing the screening test also influenced whether the patient would follow through with the test. "On the negative side, many patients parroted reports from colleagues and friends about the horrors of the prep and embarrassment related to the colorectal screening," Feeley explains. "At the same time, many parents cited children and spouses as their inspiration to get screened; loved ones often tempered the negative response about screening presented in the break room or in the hallways at work." The words of physicians also had an impact on patients" willingness to take the screening test. "One physician reported the use of analogies," Feeley says. "For example, the physician said, "It is like taking care of your car; you must change the oil and check the engine to make sure all is going well."" But the study stressed this kind of physician-patient communication that often persuades the patient to take the screening test is hampered when the visits are rushed and distracted. "Any proper attempt to allay patient fears associated with colorectal cancer screening or efforts to communicate the value of preventive medicine requires ample time for effective dialogue," Feeley says. Colorectal cancer is the second most common cause of cancer-related deaths in the United States, and the third most commonly diagnosed cancer among men and women, the researchers point out. The American Cancer Society estimates that 112,340 new cases of colorectal cancer will be identified this year, and more than 52,000 people would die from colon and rectal cancer. Most cases are detected at an advanced stage, when the chances the patient can recover decrease. The National Cancer Institute estimates that the five-year survival rate for colorectal cancer is about 70 percent. Screening patients with no symptoms of colorectal cancer for precancerous lesions greatly reduces the chances patients with these cancers will die from the disease. Although the test is quick, largely painless and not expensive, some studies estimate fewer than 45 percent of the patients who should sign up for the test actually go through with the procedure. Charles Anzalone University at Buffalo


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):